alexa Docking Studies and Evaluation of Anthranilic Acid Base
ISSN: 2161-0444

Medicinal Chemistry
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Docking Studies and Evaluation of Anthranilic Acid Based PPARδ Agonists for the Treatment of Metabolic Syndromes

Meenu Beniwal1*, Viney Lather2, Vikramjeet Judge3, Neelam Jain1 and Amit Beniwal4

1Department of Pharmaceutical Education and Research, Bhagat Phool Singh Mahila Vishvavidyalaya, Khanpur Kalan, Sonepat, Haryana, India

2Department of Pharmaceutical Chemistry, JCDM College of Pharmacy, Sirsa, Haryana, India

3Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, Haryana, India

4Combitic Global Caplet Pvt. Ltd., Sonipat, Haryana, India

*Corresponding Author:
Meenu Beniwal
Department of Pharmaceutical Education and Research
Bhagat Phool Singh Mahila Vishvavidyalaya
Khanpur Kalan
Sonepat, Haryana-131 409, India
Tel: +919467878376
E-mail: [email protected]

Received date: December 21, 2015; Accepted date: January 20, 2016; Published date: January 25, 2016

Citation: Beniwal M, Lather V, Judge V, Jain N, Beniwal A (2016) Docking Studies and Evaluation of Anthranilic Acid Based PPARδ Agonists for the Treatment of Metabolic Syndromes. Med chem 6:023-032. doi:10.4172/2161-0444.1000318

Copyright: © 2016 Beniwal M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Metabolic syndrome (MS) is defined by a cluster of interconnected factors that directlyincrease the risk of coronary heart disease (CHD), other forms of cardiovascularatherosclerotic diseases (CVD) and Type 2 diabetes mellitus (T2DM). Several studies have suggested important role of PPARδ in regulating lipid metabolism and energy homeostasis in muscle and fat. The present research work was undertaken to design and develop novel moieties derived from anthranilic acid scaffold as PPARδ agonists that can be developed further for the management of metabolic disorders. The molecules were designed using receptor based drug design approach, by utilizing the X-ray crystallographic information of PPARδ from PDB database. Based on the pharmacophoric requirements for PPARδ binding, the anthranilic acid nucleus was chosen for the design of newer analogs by substitution of amide linker and introduction of lipophilic groups on aromatic system by using sulphonamide group as a linker. Amongst the several synthesized anthranilic acid derivatives, 5-chloro-2- [3-(4-nitro-phenylsulfamoyl)-benzoyl amino]-benzoic acid showed highest antidiabetic activity. The experimental results were found to be in concordance with that of the in silico results. Overall, this research work revealed the potential of novel anthranilic acid based PPARδ agonists in the management of MS. Further, these molecules can serve as the starting point for the development of more potent lead molecules for MS.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords